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Abstract
Background: The members of the retinoblastoma protein family, pRb, p107 and pRb2 (p130), are
central players in controlling the cell cycle. Whereas disturbed function of pRb is commonly seen
in human cancers, it is still an open question whether pRb2 is involved in tumorigenic processes.
However, altered subcellular localization of pRb2 and mutations in the pRb2-encoding gene RBL2
have been described for some tumours, including Burkitt lymphomas (BL).
Methods: We retrieved 51 biopsy specimens of endemic BL cases from Uganda. The expression
of pRb2 was determined by immunohistochemistry. Exons 1922 of the RBL2 gene, the region
known to contain a nuclear localization signal, were screened for mutations by PCR amplification
and direct DNA sequencing.
Results: Nearly all of our cases (84.0%) were positive for pRb2 protein expression although this
protein is a marker for growth arrest and Burkitt lymphoma is characterized by a high proliferation
rate. Of the positive cases, 73.8% were scored as expressing the protein at a high level. Subcellular
pRb2 localization was predominantly nuclear and no cases with expression restricted to the
cytoplasm were observed. We did not detect any RBL2 mutations in the part of the gene that
encodes the C-terminal end of the protein.
Conclusion: The majority of endemic BL cases from Uganda express pRb2, but somatic RBL2
mutations affecting the protein's nuclear localization signal appear to be rare.
Background
The retinoblastoma protein pRb and its relatives p107 and
pRb2 (p130) constitute a family of proteins sharing com-
mon structural organization and significant degree of
sequence similarity. These proteins have critical functions
in the control of cell proliferation and differentiation
[1,2]. Each of the three proteins can elicit G1 growth arrest
by binding to and inhibiting the E2F transcription factors.
The retinoblastoma (Rb) family of proteins exhibit their
growth-suppressive properties in a manner which is both
cell type- and cell cycle-dependent. Hence, they are not
functionally redundant although they may complement
each other [2-4].
Published: 19 August 2009
BMC Clinical Pathology 2009, 9:6 doi:10.1186/1472-6890-9-6
Received: 29 December 2008
Accepted: 19 August 2009
This article is available from: http://www.biomedcentral.com/1472-6890/9/6
© 2009 Kalungi et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.BMC Clinical Pathology 2009, 9:6 http://www.biomedcentral.com/1472-6890/9/6
Page 2 of 7
(page number not for citation purposes)
The normal functions of the Rb protein family may be
down-regulated or completely ablated by a variety of
mechanisms including mutations [1,5]. Deletions and
other alterations of the genes that participate in the regu-
lation of Rb proteins, such as CDKN2A,  CDK4  and
CCND1, occur frequently in many tumours [6,7]. This
illustrates that disruption of the signaling pathway in
which pRb, p107 and pRb2 act, is a common event in
tumorigenesis.
Among the members of the Rb protein family, pRb2 is the
most abundant in G0. It maintains G0 arrest in quiescent
or differentiated cells, controls the transition from G1 to S
phase, and is a key regulator of growth arrest in cellular
senescence [8]. The RBL2 gene, which encodes the pRb2
protein, contains 22 exons [9] and has been mapped to
human chromosome 16q12.2 [10]. The pocket domain of
pRb2 is encoded by exons 1013 (domain A) and 1720
(domain B). The term 'pocket' relates to the conserved
domain through which pRb, p107 and pRb2 bind viral
oncoproteins and cellular transcription factors of the E2F
family [1]. Notably, the pRb2 protein depends upon cor-
rect subcellular localization and one or more nuclear
localization signals (NLS) in order to achieve full biologi-
cal activity [11].
Expression of pRb2 has been demonstrated in a variety of
normal tissues and tumours, for example in hematopoi-
etic and epithelial cells [12], atypical endometrial hyper-
plasia and carcinoma [13] and non-Hodgkin lymphomas
[14]. The protein has been reported to be involved in the
pathogenesis and progression of vulvar squamous cell car-
cinomas [15] and salivary gland tumours [16] and may
predict prognosis in choroidal melanomas [17]. The role
of pRb2 in cancer development is, however, still debata-
ble [18]. For instance, pRb2 is not of prognostic signifi-
cance in cervical intraepithelial neoplasia [19]. Moreover,
loss of this protein may not be sufficient to deregulate the
orderly progression of the cell cycle, as mice unable to
express pRb2 do not exhibit any altered tumour predispo-
sition or developmental defects [3].
The pRb2-containing genomic region, i.e. the long arm of
chromosome 16, is often lost in carcinomas of the breast,
prostate, liver, and ovary [20-23]. Somatic mutations in
the RBL2 gene have, however, rarely been reported. The
few examples include a small cell lung cancer cell line [24]
and nasopharyngeal carcinoma from Northern Africa
[25]. There are conflicting findings in Burkitt lymphomas
(BL) where RBL2 mutations were observed in 11 of 13
endemic African cases, whereas AIDS-related BL showed
no mutations [26]. In a series of sporadic BL from Brazil
no mutations in the RBL2 gene were found [27].
The aim of this study was to investigate pRb2 expression
in endemic BL cases from Uganda and to search for
tumour-associated, somatic RBL2 mutations that could be
involved in deregulated cell cycle control.
Methods
Selection of cases and conventional histology
Formalin-fixed paraffin-embedded tissue blocks from
cases of BL were obtained from the archives of the Depart-
ment of Pathology, College of Health Sciences, Makerere
University, Kampala, Uganda. The sections were re-
embedded at the Department of Pathology, the Gade
Institute, Haukeland University Hospital. Before pathol-
ogy re-investigation was done, all specimens were
delinked from personal identifiers. The cases were revised
by two pathologists (SK, LB) to confirm the histological
diagnosis of BL. The final diagnosis was based on a com-
bination of characteristic histology and immunopheno-
type (CD45+, CD20+, CD10+, BCL6+, BCL2- and Ki-67 >
95%). Information on age, sex and site of biopsy was
obtained when available. Permission to perform the study
including accessing the lymphoma samples was obtained
from the Pathology Department, Makerere University,
Faculty of Medicine (now College of Health Sciences),
Kampala, Uganda. Further ethical approval and material
transfer agreement were not compulsory at the time the
study was initiated. The Norwegian part of the study was
covered by a project approval by the University of Bergen
and by the Department of Pathology, Haukeland Univer-
sity Hospital's general permission to investigate material
from human beings. The study was carried out according
to the Helsinki Declaration.
Immunohistochemistry
Five-μm sections of the tissue blocks were cut and placed
on sialinized microscope slides. Immunostaining was per-
formed using the automated immunohistochemical stain-
ing system TechMate (Dako, Glostrup, Denmark) after
heat-induced epitope retrieval. The sections were first
deparaffinized and hydrated through a graded series of
alcohol and water. The antigen retrieval procedure
involved the use of a microwave oven for pre-heating the
slides in retrieval buffer (10 mM Tris, pH 9.0; 1 mM
EDTA) for 10 minutes until boiling, then heating for addi-
tional 15 minutes. Endogenous peroxidase activity was
blocked by treatment with hydrogen peroxide S2001
(Dako) for 5 minutes. The slides were then incubated for
60 minutes with an Rb2/p130 monoclonal antibody
diluted 1:100 (clone 130P215 from Abcam, Cambridge,
U.K). The antibody clone 130P215 was raised against a
peptide corresponding to amino acids 878913 of human
pRb2, thereby recognizing a region near the C-terminus
but different from the region screened in the mutational
analysis. Detection of antibody binding was performed
using the Envision HRP kit K4061 (Dako). Heamatoxylin
was used as a counter stain. The pRb2 staining pattern was
evaluated as high (more than 50% of the tumour cells
staining), low (1%50% of tumour cells staining), orBMC Clinical Pathology 2009, 9:6 http://www.biomedcentral.com/1472-6890/9/6
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absent (no staining). A tissue micro array (TMA) block
was made from 1-mm cylinders punched out from a rep-
resentative tumour area of each BL case. As validation of
the staining interpretation, whole sections from ten of the
TMA cases were cut, treated and evaluated in the same way
as the TMA block.
DNA extraction from tissue sections
Depending on the size of the tumour tissue, two or three
8-μm sections were cut. The sections were placed in 190 μl
buffer G2 and 10 μl proteinase K solution of the MagAt-
tract DNA mini M 48 kit (Qiagen, Hilden, Germany) and
dissolved by shaking overnight at 56°C. DNA was then
purified by using this kit in combination with a GenoM48
BioRobot system (Qiagen) in accordance with the manu-
facturer's instructions. All 14 cases selected for the molec-
ular genetic analysis were regarded as classical BL.
PCR and DNA sequencing
Exons 1922 were PCR-amplified (exons 19, 20 and 22 as
two overlapping fragments) and screened for mutations
by direct sequencing. Primer sequences are given in Table
1. The exon 21 product did not fully cover the exon, but
included all regions where RBL2  mutations have been
reported previously [26]. In general, PCR reactions were
run in a total volume of 25 μl with 0.3 μM of each primer
using the AmpliTaq Gold PCR Mastermix (Applied Bio-
systems, Foster City, CA, USA) or Taq DNA polymerase
with Q-solution (Qiagen). Samples were subjected to ini-
tial denaturation at 95°C for 15 min, 4550 cycles at 95°C
for 50 s, annealing (see Table 1 for temperatures) for 50 s,
and elongation at 72°C for 1 min, followed by a final
elongation step at 72°C for 7 min. PCR products were
purified by using enzymatic treatment with ExoSAP-IT
(USB, Cleveland, OH, USA). The sequencing primers were
identical to the PCR primers and the PCR products were
sequenced in both directions employing the BigDye Ter-
minator Cycle Sequencing kit, Version 1.1 (Applied Bio-
systems). The sequence reactions were analyzed on an ABI
Prism 3100 Genetic Analyzer with Sequencing Analysis
software, Version 3.7 (Applied Biosystems).
Statistical analysis
Pearson's chi-square test was used to evaluate any rela-
tionships between the different clinicopathological
parameters. A result was considered significant when its p-
value was < 0.05. The statistical software package SPSS,
Version 15 was used.
Results
A total of 51 BL cases were included in the study, 21
(41.2%) of whom were males and 29 (56.9%) females.
The gender was unknown in one case. The mean age of the
patients was 6.9 years and the median was 7 years with a
range of 313 years. Features of the cases included in the
study are listed in Table 2. Facial tumours (n = 26; 51.0%)
were more abundant than abdominal tumours (n = 21;
41.2%). The site of the tumour was unknown in four
(7.8%) cases. Of the facial tumours, oral tumours were
most common (n = 23) with the remaining three cases
arising from the orbit. Thirteen of the abdominal tumours
were from the ovary, one from the testicle, one from the
kidney, one from the liver and five from unspecified sites
in the abdomen. Oral cavity tumours were more common
among the males while abdominal tumours dominated
among the females. Facial tumours were more frequent in
children below eight years but this association between
tumour site and patient age did not reach statistical signif-
icance (p = 0.08).
Forty-two (84.0%) of the 50 cases for which immunohis-
tochemical data could be obtained, stained positively for
pRb2 while eight (16.0%) were negative (Table 2).
Among the positives, immune reactivity varied from close
to 100% of the tumour cells to only a few positive cells in
the section (Figure 1A1C). The staining was predomi-
Table 1: Primers used for amplification and sequencing of the RBL2 gene.
Exon Primer sequence (5'-3') Annealing temperature Product size (bp)
19-1 Forward AGGGTGTGCTCAACAAATAC 50 142
Reverse CTGTTGGAGAATTCTGATGG
19-2 Forward TCTCTAAAGGTGTATAGAAGTG 50 161
Reverse GAAAAGCTCCTAATTTTGTC
20-1 Forward ATTAGCAGCCTTTGTACTGAC 55 148
Reverse ACTGTTGGCACCTGTGAGG
20-2 Forward AGCAGTGCTCCTCCCACA 50 174
Reverse AAAGTATGAAATAATCCCTG
21 Forward CTCTCTCCCTATCCATTTG 50 143
Reverse GGACTGTTGCTGAAGTAATAG
22-1 Forward CTGAGCTATGTGCATTTGCA 52 148
Reverse TTTGCAGGTGATTCACTTCC
22-2 Forward AAAGAGAGGAATTCTTTTGG 54 145
Reverse AGAGTTTAATACAAGAGACTBMC Clinical Pathology 2009, 9:6 http://www.biomedcentral.com/1472-6890/9/6
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Table 2: Clinical information and pRb2 staining scores for the studied BL cases.
Case number Age Sex Biopsy/tumour site pRb2 TMA staining score*
1 6 F Palate 3
2 6 F Ovary 3
3 7 F Buccal cavity 3
4 7 M Gingiva 3
5 5 F Gingiva 3
6 6 F Ovary 3
7 6 F Buccal cavity 1
8 7 F Buccal cavity 2
9 7 F Ovary 3
10 8 F Ovary 3
11 7 M Unknown 3
12 6 M Gingiva 3
13 4 M Unknown 3
14 5 M Jaw 3
15 9 M Abdomen 3
16 9 F Abdomen 1
17 7 M Gingiva 3
18 7 F Kidney 2
19 12 F Ovary 2
20 4 F Gingiva 3
21 4 F Gingiva n.a.
22 13 M Liver 3
23 13 F Abdomen 3
24 7 M Orbit 3
25 5F O v a r y 3
26 3F O v a r y 1
27 3F O v a r y 3
28 5F O v a r y 3
29 5M O r b i t 3
30 n.a. n.a. Unknown 3
31 12 F Abdomen 3
32 12 F Gingiva 3
33 5M J a w 2
34 8 F Ovary 2
35 6 M Abdomen 3
36 8F J a w 3
37 5 M Orbit 1
38 5 M Gingiva 2
39 8 F Ovary 2
40 5 F Ovary 1
41 5 F Jaw 2
42 7 F Ovary 2
43 6 M Gingiva 3
44 7 M Gingiva 3
45 5 M Testis 1
46 8 M Gingiva 1
47 8 F Unknown 3
48 8 M Gingiva 1
49 6 F Jaw 3
50 7 M Jaw 2
51 5 M Jaw 2
* 1 = absent (0% of tumour cells staining); 2 = low (150% of tumour cells staining); 3 = high (>50% of tumour cells staining). Case numbers in bold 
indicate those cases from which biopsy tissues were used in the mutation analysis. n.a. = not available.BMC Clinical Pathology 2009, 9:6 http://www.biomedcentral.com/1472-6890/9/6
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nantly nuclear. Also, cells undergoing mitosis were posi-
tive, with immune reactivity present throughout the
cytoplasm (Figure 1D). Table 2 shows the staining scores
for the cases included in the study. We did not find any
statistically significant association between pRb2 staining
(positive/negative) and age below 8 years (p = 0.69), or
gender (p = 0.71), or tumour site (p = 1.00). Of the 42 pos-
itive cases, 31 (73.8%) cases were scored as highly express-
ing tumours and 11 (26.2%) as low-expressing. pRb2
staining (high versus low) did not show any statistically
significant association with tumour site (p = 0.86), gender
(p = 0.88), or age (p = 0.71).
Fourteen cases were selected for mutation analysis. The
criteria for selection were classical BL histopathology, ade-
quate amount of tissue available for repeated DNA extrac-
tion and a high ratio of lymphoid cells versus other cells
in the section. Exons 1922 whose C-terminal part encodes
a pRb2 nuclear localization signal and where mutations
have been reported previously, were screened. We were
able to amplify and sequence 9/14 (64%) of the cases for
exon 19-1, 12/14 (86%) for 19-2, 10/14 (71%) for 20-1,
8/14 (57%) for 20-2, 12/14 (86%) for exon 21, and 11/14
(79%) for exons 22-1 and 22-2. Three or more exons
could be amplified in twelve of the cases, two exons in one
case and one exon in one case. We did not detect RBL2
mutations in any of the exons. Figure 2 illustrates the
DNA sequences from representative BLs in our study.
Discussion
In the present study, we have analyzed pRb2 expression
and searched for RBL2 mutations in endemic Burkitt lym-
phoma from Uganda. The median age of the patients in
our material was 7 years, similar to what other reports on
BL from Uganda have indicated as typical [28,29]. The
number of oral tumours in our series is almost equal to
that of abdominal tumours. Some studies have suggested
a preponderance of oral tumours in BL, others have
reported that abdominal tumours are most frequent [29-
31]. Oral tumours may predominate in clinical series
because they are easily seen, cause difficulty in feeding due
to loosening of teeth and are disfiguring so medical atten-
tion is sought early. Oral tumours are also more accessible
for biopsy compared to BL in other sites. Among males
with BL, we found oral tumours to be most common,
whereas in females, tumours of the ovary predominated.
The majority of tumours in our series (84.0%) were posi-
tive for pRb2 expression. In a series of untreated patients
with non-Hodgkin's lymphoma (various types), low lev-
els of pRb2 were reported to correlate with high levels of
p107 and proliferation-associated proteins [32]. It may
therefore seem surprising that BLs, having a proliferation
rate close to 100%, express high levels of pRb2, which is
considered a marker of growth arrest. The explanation
could be that the pRb2 pathway is functionally impaired
in BL, expression being deregulated along the cell cycle or
the protein accumulating due to inhibited degradation. In
this regard, it is noteworthy that high levels of pRb expres-
sion, the canonical member of the retinoblastoma protein
family, has been found in high growth rate lymphomas
[33].
High expression of pRb2 has also been linked to virus-
associated oncogenesis [34]. Because endemic BL is asso-
ciated with Epstein-Barr virus in at least 95% of the cases
[30], a possible scenario could be that the pRb2 level
increases in response to viral oncogenic activity. This
might also explain the observation that pRb2 expression
is elevated in AIDS-related lymphomas [14], although the
fundamental differences between HIV and Epstein-Barr
virus should be kept in mind.
The proportion of tumours with absent pRb2 expression
(16.0%) in our series is comparable to what has been
reported in non-lymphoid tumours [35,36]. Loss of pRb2
expression could be caused by inactivating mutations (as
in other tumour suppressor genes) or by stimulated deg-
radation. It remains to be investigated whether BLs nega-
tive for pRb2 constitute a subset of tumours with specific
biological properties affecting for example patient sur-
vival.
The staining pattern in our pRb2-positive BL cases, was
predominantly nuclear. In normal tissues, pRb2 expres-
Representative examples of pRb2 staining in BL patients from  Uganda Figure 1
Representative examples of pRb2 staining in BL 
patients from Uganda. A) Negative staining (original mag-
nification: ×400). B) Low staining, i.e. less than 50% of 
tumour cells expressing pRb2 (original magnification: ×400). 
C) High staining, i.e. more than 50% of tumour cells express-
ing pRb2 (original magnification: ×400) D) Cytoplasmic 
expression of pRb2 in tumour cells undergoing mitosis. 
Dividing cells are indicated by arrows (original magnification: 
×630).BMC Clinical Pathology 2009, 9:6 http://www.biomedcentral.com/1472-6890/9/6
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sion has been reported to be confined to cell nuclei and
the perinuclear membrane [12]. Concomitant nuclear
and cytoplasmic staining has been observed in prostate
cancer and hepatocellular carcinoma cells [35,36]. Nor-
mal human lymphocytes and osteosarcoma cell lines
exhibited exclusive nuclear pRb2 localization whereas
lymphoid tumour cell lines were noted to express the pro-
tein in the cytoplasm [37]. Cytoplasmic pRb2 staining
was also reported in the cases of endemic BL which had
RBL2  mutations [26]. The cytoplasmic localization of
pRb2 in BL tumour tissue and in lymphoid cell lines has
been attributed to mutations which lead to disruption of
the NLS [26,37]. However, other authors have reported
that neither deletion nor mutation of C-terminal NLS
sequences resulted in complete abolishment of nuclear
pRb2 localization [11]. The observed differences in level
of expression and subcellular localization of pRb2 may be
due to differences in the phases of the cell cycle in which
the cells are studied, hyperphosphorylation of the protein
which may affect NLS activity, the presence of nucleocyto-
plasmic protein shuttling and, of course, to different prop-
erties of the antibodies used for detection.
We did not observe any mutations in RBL2 in exons 1922
in the 14 cases that we examined. Our results are therefore
in contrast with those of Cinti et al. [26] who reported
RBL2 mutations in 11 of 13 endemic BL cases from Kenya.
We cannot exclude the possibility that the discrepancy is
explained by inherent differences in materials from
Uganda and Kenya regarding patient-specific and/or viral-
specific factors. A limitation of our study is that we were
not able to amplify and sequence all four exons in all
cases, probably because of the varying fixation conditions
(including the use of unbuffered formalin) in the African
material. We nevertheless found that RBL2  mutations
must be rarer in BL than previously suggested, a conclu-
sion which is supported by the report of Klumb et al. [27]
who were unable to detect such mutations in sporadic BL
from Brazil. Moreover, none of our cases showed predom-
inant cytoplasmic staining which could indicate the pres-
ence of mutations. Finally, we note that in the Catalogue
of Somatic Mutations in Cancer (COSMIC, see http://
www.sanger.ac.uk/genetics/CGP/cosmic) there are no
entries of somatic mutations in the RBL2 gene, despite
recent large-scale efforts to sequence cancer cell genomes.
Conclusion
We have shown that endemic Burkitt lymphoma from
Uganda tend to express pRb2, a cell cycle protein associ-
ated with growth arrest, although intense cell prolifera-
tion is a characteristic feature of this cancer type. However,
somatic mutations in the part of the RBL2 gene that is
important for nuclear localization, appear to be rare.
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